There's a big payday ahead for the people behind the bio-tech company Idenix.
Idenix shares went triple on the news oof a $3.85 billion buyout deal with Merck.
Boston Business Journal's bioflash editor, Don Seiffert, says the annoucement was made Monday morning.
"It's still in discussions, but the board of both companies have voted in favor of it. It's supposed to be closing by the end of September, I believe," he said.